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Abstract
Background: We wanted to define metabolomic patterns in plasma to predict a negative outcome in severe
trauma patients.
Methods: A prospective pilot study was designed to evaluate plasma metabolomic patterns, established by liquid
chromatography coupled to mass spectrometry, in patients allocated to an intensive care unit (in the University
Hospital Arnau de Vilanova, Lleida, Spain) in the first hours after a severe trauma (n = 48). Univariate and multivariate
statistics were employed to establish potential predictors of mortality.
Results: Plasma of patients non surviving to trauma (n = 5) exhibited a discriminating metabolomic pattern, involving
basically metabolites belonging to fatty acid and catecholamine synthesis as well as tryptophan degradation pathways.
Thus, concentration of several metabolites exhibited an area under the receiver operating curve (ROC) higher than 0.84,
including 3-indolelactic acid, hydroxyisovaleric acid, phenylethanolamine, cortisol, epinephrine and myristic acid.
Multivariate binary regression logistic revealed that patients with higher myristic acid concentrations had a non-survival
odds ratio of 2.1 (CI 95% 1.1–3.9).
Conclusions: Specific fatty acids, catecholamine synthesis and tryptophan degradation pathways could be implicated
in a negative outcome after trauma. The metabolomic study of severe trauma patients could be helpful for biomarker
proposal.
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Background
Severe trauma injuries are the first cause of mortality
among population younger than 44. With a global mor-
tality higher than 5 million individuals/year its clinical
assessment and care is a first order public health ques-
tion [1]. The use of clinical scores such as APACHE II
and SAPS in intensive care units (ICU) have improved
the follow-up [2]. However, even considering those
scores specifically developed for trauma injuries (e.g.
TRISS, TRAM, RISC), these exhibit a large space for im-
provement in calibration and discriminative power [3].
Accordingly, there is a need for biomarker characterization
in order to improve precise measurements of severity and
pathophysiological consequences, hereby improving their
early, scientifically-guided, therapeutic approaches overall
leading to a better prognosis [4, 5]. The search for bio-
markers has been usually performed within the sepsis con-
text. Though there have been described more than 170
potential biomarkers, still these have not reached the
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usefulness for prediction of severity and progression of in-
fective processes [6, 7].
In contrast with the development in sepsis, biomarker
searching in trauma patients is less advanced, being
mostly restricted to traumatic brain injury (TBI). In this
context, some of the reported markers show a good cor-
relation with severity, brain damage and global outcome
[8]. However, the use of these markers cannot be extended
to other trauma types. In search of novel biomarkers to
shed light upon pathophysiology venues, one should
consider metabolomics. The use of metabolomics tech-
niques allows the study of the complete set of
low-molecular-weight intermediates (metabolites), which
vary according to the pathologic state of the cell, tissue,
organ, or organism and are context-dependent [9]. This
approach offers a high number of potential biomarkers
when combining the use of high-resolution chromato-
graphic techniques with mass-spectrometry. The use of
metabolomics in critical care management could help to a
global understanding on metabolism after injury therefore
leading to rationally derived therapeutic measures [6, 10].
Globally, despite there have been previous reports on
the use of metabolomics in acute trauma care in the in-
tensive care unit, these have been often restricted to the
TBI context and/or non-chromatographic techniques
(reviewed in [11]). To overcome these limitations, in the
present work we have analyzed the metabolomic profiles
of severe trauma patients admitted to an ICU, by com-
paring the early metabolomicprofiles of those patients
who survived the trauma versus the ones belonging to
non-survivors. The fact that a single metabolite may pre-
dict the fatal outcome after multiple injuries can be
questioned. For this reason, we also evaluated if the total
profile of metabolites recorded within 48 h after the
trauma may define the risk of death within 14 days after
admission to the intensive care unit. The results demon-
strate the potential existence of early metabolomics
markers of trauma-associated mortality.
Methods
Study design and participants
A prospective pilot study was designed with patients allo-
cated to an ICU (Arnau de Vilanova University Hospital,
Lleida, Spain) after a severe trauma. Protocol was super-
vised and approved by the Institutional Ethics Committee
of the Arnau de Vilanova University Hospital. All partici-
pants (or their legal representatives) gave their written
consent for the study. Inclusion criteria were all
trauma-affected patients with severe status requiring ICU
admission caused by a traumatic event in the prior 48 h,
age > 16 years, with a follow-up period of 14 days in the
ICU, in the period between 2011/10/01 and 2012/11/15.
All patients whose samples were not obtained in the first
48 h were excluded.. Similarly, we excluded patients with
acute kidney failure, defined as plasma creatinine higher
than 1.5 times comparing to initial values or diuresis <
400ml/24 h. Table 1 shows clinical features of included
patients. None of the participants received artificial nutri-
tional support in the first 48 h in ICU. Nutritional specific-
ities were chosen on each patient individual basis, mainly
according the possibility of enteral pathway and did not
influence survival outcome.
Variables registered
Age, gender, length of ICU stay (LOS), Injury Severity
Score (ISS) [12], Acute Physiology and Chronic Health
Table 1 Demographic and clinical characteristics according to mortality
ALL
(n = 48)
SURVIVORS
(n = 43)
NON SURVIVORS
(n = 5)
p*
Age (years)a 47,5 ± 19 45,7 ± 19 63,0 ± 10 0,057
Sex (Male) (%) 85,4 83,7 100,0 0,438
Traffic (%) 62,5 62,8 60,0 0,706
Severe Brain Injury (Glasgow score < = 8) (%) 37,5 34,9 60,0 0,272
Glasgow (score) 13 ± 3 13 ± 3 14 ± 3 0,533
MV (%) 37,5 30,2 100,0 0,005
NA (%) 33,3 30,2 60,0 0,316
PaO2/FiO2 305 ± 111 310 ± 112 265 ± 99 0,429
LOS (days)b 13(8–24) 16(8–28) 9(4–14) 0,001
APACHE II 11,6 ± 6 10,7 ± 6 19,0 ± 5 0,010
ISS 19,0 ± 9 18,9 ± 9 20,2 ± 7 0,511
Both APACHE II and ISS scores are directly proportional to severity of injury
MV Mechanical ventilation, NA noradrenaline perfusion, PaO2/FiO2 Arterial Partial Pressure of Oxygen/Fraction of Inspired Oxygen, LOS Length of stay, APACHE II
Acute Physiology and Chronic Health Evaluation II (ranges between 0 and 67), ISS Injury Severity Score (ranges between 0 and 75)
*p value after group comparison by χ2 or Mann-Whitney test for continuous variables
amean ± standard deviation
bmedian (interquartile interval)
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Evaluation (APACHE II) [13]classification and mortality
at 14 days were recorded. We also registered the severity
of loss of respiratory function, measured as the lowest
PaO2/FiO2 in the first 24 h of ICU admission, by using
arterial gasometry, as well as mechanic ventilation (MV)
need. Hemodynamic instability (shock) was diagnosed as
the patient having a maintained (> 2 h) low systolic
blood pressure level (< 90mmHg) and/or requiring nor-
epinephrine. Transfusion need was defined as those pa-
tients requiring more than one hemoconcentrate, and
coagulopathy was defined as Quick score < 70% and/or
thrombocyte count < 100,000/μL. All scales were vali-
dated by 2 independent evaluators.
Sample processing
Blood was obtained in all cases by standard venipuncture
or central venous catheterisation, between 24 and 48 h after
the traumatic event in sodium citrate tubes. Immediately
after sampling, diethylpentaacetic acid (1mM) and
butyl-hydroxy-toluene (10 μM) were added to the sample,
in order to avoid artefactual oxidation. Plasma was obtained
after centrifugation at 3000 x g, 4 °C for 10min, and ali-
quoted into cryovials for immediate storage at − 80 °C.
Samples were processed in a double-blind fashion, being
aleatorized for extraction and injection. Metabolites from
plasma were extracted as previously described [14]: samples
were thawed at 4 °C, and 300 μl of cold methanol (contain-
ing 1 μg/ml of 13C-phenylalanine as internal standard) were
added to 100 μl of plasma for deproteinization, followed by
incubation at − 20 °C for 1 h and then, centrifuged at
12000 g for 3min. The supernatants were recovered, evapo-
rated using a Speed Vac (Thermo Fisher Scientific, Barce-
lona, Spain) and re-suspended in water 0.4% acetic acid/
methanol (50/50).
Metabolomic analyses
For the metabolomic study, an Agilent 1290 liquid chro-
matography system coupled to an ESI-Q-TOF MS/MS
6520 instrument (Agilent Technologies, Santa Clara,
CA, US) was used. In all cases, 2 μL of extracted sample
was applied onto a reversed-phase column (Zorbax
SB-Aq 1.8 μm 2.1 × 50mm; Agilent Technologies)
equipped with a precolumn (Zorbax-SB-C8 Rapid Reso-
lution Cartridge 2.1 × 30mm 3.5 μm; Agilent Technolo-
gies) with a column temperature of 60 °C. The flow rate
was 0.6 mL/min. Solvent A was composed of water con-
taining 0.2% acetic acid and solvent B was composed of
methanol 0.2% acetic acid. The gradient started at 2% B
and increased to 98% B in 13min and held at 98% B for
6 min. Post-time was established in 5min.
Data were collected in positive electrospray mode time
of flight operated in full-scan mode at 100–3000 m/z in
an extended dynamic range (2 GHz), using N2 as the
nebulizer gas (5 L/min, 350 °C). The capillary voltage
was 3500 V with a scan rate of 1 scan/s. The ESI source
used a separate nebulizer for the continuous, low-level
(10 L/min) introduction of reference mass compounds:
121.050873, 922.009798 (positive ion mode) and
119.036320, 966.000725 (negative ion mode), which were
used for continuous, online mass calibration. MassHun-
ter Data Analysis Software (Agilent Technologies) was
used to collect the results, and MassHunter Qualitative
Analysis Software (Agilent Technologies) to obtain the
molecular features of the samples, representing different,
co-migrating ionic species of a given molecular entity
using the Molecular Feature Extractor algorithm (Agi-
lent Technologies), as described [14, 15]. Finally, Mas-
sHunter Mass Profiler Professional Software (Agilent
Technologies) and Metaboanalyst platform [16] were
used to perform a non-targeted metabolomic analysis of
the extracted features. We selected samples with a mini-
mum of 2 ions. Multiple charge states were not consid-
ered. Compounds from different samples were aligned
using a retention time window of 0.1% ± 0.25 min and a
mass window of 10.0 ppm ±2.0 mDa. We selected only
those features in the 80-100th quartile of relative abun-
dance and corrected for individual bias.
Statistical analyses
The data are presented either as the mean ± standard de-
viation, the median (interquartile range) or as a percent-
age. Differences between survivor and non-survivors
(NS) were evaluated with Chi-squared (for discrete vari-
ables) or with Mann-Whitney test by using the SPSS
software ver 24 (IBM Corp, Armonk, NY, USA).
For metabolomic-derived variables, after log trans-
formation and auto scaling of their abundances, multi-
variate statistics including Hierarchical Clustering,
principal component analyses (PCA) and partial least
square discriminant analyses (PLS-DA) were done using
the Metaboanalyst platform [16]. The same platform was
employed to evaluate differences between survivors and
non surviving patients were evaluated by Student’s t test
(p < 0.05), to generate receiver operating characteristic
(ROC) curves, and to explore pathway impact (using
hypergeometric test of over representation analyses). In
the case of ROC curves, data were not log transformed
nor autoscaled, being used the raw values of MS counts.
The identity of differential metabolites were annotated
by searching their characteristics in the PCDL database
from Agilent (Agilent Technologies, Barcelona, Spain),
which uses retention times in a standardized chromato-
graphic system as an orthogonal parameter to comple-
ment accurate mass data (accurate mass retention time
approach) according to previously published works [16].
Mortality risk was calculated with binary regression lo-
gistic (both univariate and multivariate) by calculating
odds ratio (OR) and confidence intervals (95%). Those
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markers with better discriminatory power according
ROC curves were used. For the multivariate model we
included those variables showing significance in the uni-
variate approach, by using an stepwise selection type.
Results
Table 1 shows clinical features of enclosed patients. APA-
CHE II scores were significantly different between both
groups (trauma surviving and non-surviving patients) ana-
lyzed. This agrees with previous data, showing that scores
higher than 15 points have an overall mortality near 25%,
and those scores higher than 25 a mortality of 50% [17] .
When evaluating differences between trauma surviving
and non-surviving patients there were almost significant
differences in age, VM and LOS. All 5 non-surviving pa-
tients were victims of a high energy impact (traffic crash
casualties or high level fall). In 4 cases, there was general-
ized hypoperfusion (haemorragic shock and hypoxia) and
1 case it was almost exclusively due to TBI. Of note, one
of non-surviving patients had a very differential metabolo-
mic signature (Addittional file 1: Figure S1). As it is
shown, this patient presents very different relative abun-
dance of all the metabolites and arouse as a potential out-
lier. When clinical parameters were check out we
discovered that this patient suffered from amyotrophic lat-
eral sclerosis so we discarded the corresponding metabo-
lomics profile for further multivariate analyses, with TBI
as predominant mechanism. No patients with sepsis were
present in our cohort.
By employing metabolomics we were able to detect 2084
molecular features in plasma (see Declaration section for data
availability). As shown in Fig. 1, plasma from non-surviving
patients exhibited a specific metabolomic signature in plasma
(Fig. 1a) by both PLS-DA and hierarchical clustering analyses.
The most important metabolites defining this signature are
shown in Fig. 1c. Among them, we were able to identify
L-Tyrosine, Uric acid, 2-Amino-3-methyl-1-butanol, hypo-
xanthine and L-Isoleucine. As shown in Fig. 1b the discrimin-
ation between groups using hierarchical clustering algorithm
with 25 molecules with the lowest p value (T-Student Test)
had a non-optimal performance, with some surviving patients
clustered together with non-surviving patients.
When applying univariate analyses (Student T-Test) 84
significantly different molecules (p < 0.05, 10 upregulated
in surviving patients, 74 in non-surviving patients) ap-
peared (Table 2 for annotated molecules and Add-
itional file 1: Table S1 for full details). In order to define
the capacity of specific metabolites as potential bio-
markers, ROC curves were also performed using those
metabolites in 80-100th percentile of abundance. Among
the ROC curves with higher area under the curve (AUC),
we selected those annotated with a potential identity bas-
ing on exact mass and retention time (Fig. 2). All these se-
lected metabolites (3-Indolelactic acid (AUC: 0.938),
hydroxyisovaleric acid (AUC: 0.904), phenylethanolamine
(AUC: 0.875), cortisol (AUC: 0.865), epinephrine (AUC:
0.865), and myristic acid (AUC: 0.846)) were increased in
plasma of non-surviving patients. To further evaluate the
capacity of these metabolites we combined their values.
Figure 2g shows that combining all these selected metabo-
lites we achieved an AUC= 0.9 and, interestingly, using
only the values of cortisol and myristic acid the AUC
values reach 0.965. The discrimination capacity was lower
than those of APACHE II or ISS (Table 1). Further, no sig-
nificant correlation was found between these clinical scores
and chosen metabolites for further analyses (cortisol, myr-
istic acid), as shown in Table 3. Nonetheless, as shown in
Table 4, these metabolomic biomarkers, as well as APA-
CHE II score, were considered risk factors in univariate
mortality risk. Noteworthy, myristic acid level was the only
independent risk factor in multivariate models of mortality.
Pathway analyses reveal the 11 annotated metabolites
clustered (p = 0.11) along several amino-acid related
pathways (Fig. 3), including fatty acid biosynthesis, and
tryptophan and tyrosine metabolism.
Discussion
The presented results highlight the usefulness of meta-
bolomic approaches in the characterization of patho-
physiological events after severe trauma, as suggested by
previous reviews [11]. To the best of our knowledge, this
is one the first reports using untargeted liquid chroma-
tography coupled to mass spectrometry (LC-MS) in
plasma for a non-favorable outcome in a severe trauma
population. Previous results, using nuclear magnetic res-
onance (NMR) have shown that there are clear age and
gender-dependent differences in energy metabolism and
oxidative stress response in case-control approaches
[18]. In a similar case-control study, Brodie et al. showed
metabolomics changes in oxidative stress, nucleotide
synthesis and muscle catabolism [10], but in this case,
they employed targeted LC-MS. However, the study was
not addressed for mortality. In a similar study, compris-
ing 95 severely injured patients, targeted metabolomics
for lactate and succinate revealed its potential as
markers for negative outcome [19]. Similarly, an
NMR-based study in the context of combat injuries re-
vealed also succinate as marker of mortality, in addition
to malonate [20]. However, the number of metabolites
potentially detectable are lower than in our study, for
technical limitations. Other studies have focused on the
use of plasma metabolomics in TBI management [21,
22], even using cerebrospinal fluid [23] or urine [24] as
the sample of reference. Similarly, in a case-control
approach, other researchers indicate that a low number
of metabolites, one of them stearic acid, allowed for dif-
ferentiation of TBI from controls, and even helped to
classify TBI patients according severity [25].
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In our cohort, six annotated metabolites defined sur-
vival chances with a very high accuracy. The finding of
cortisol agrees with previous reported data [26]. How-
ever, these contrast with other reports [27], where
vasopressor-dependent critical illness individuals do not
show the same behavior. Differences in gender, organ
dysfunction and other clinical features could explain this
difference. Pathophysiologically, this could be linked to
poor glycemic control attributable to high cortisol levels
[28]. Interestingly, cortisol is one of the physiological
mediators of hyperaminoacidemia [29] and increased
branched chain aminoacid levels [30] found in the post-
injury phase by previous metabolomic approaches [10].
Of note, epinephrine also predicted low chances of sur-
vival. This result agree with previous series, where high
catecholamine values were associated to adverse cardiac
events [31], or to higher mortality, via endothelial damage
and glycocalix degradation, as well as hyperfibrinolysis
[32]. The increase of the trace amine phenylethanolamine
can be ascribed to the same phenomenon, as it is consid-
ered a by-product of catecholamine synthesis [33, 34].
Nonetheless, no previous report on its usefulness as mor-
tality biomarker was present.
3-indolelactic acid is a metabolite of tryptophan deg-
radation [35]. No previous results related this metabolite
to non-favorable outcome in trauma. Recent metabolo-
mics reports indicate that this marker is decreased in
plasma of patients with cachexia [36]. Nonetheless, pre-
vious results with experimental models of cardiac arrest,
reveal that tryptophan catabolism was directly related to
non-survival outcome [37]. Similarly, high catabolism of
tryptophan has been also associated to mortality in
Fig. 1 Patients non surviving severe trauma exhibit a metabolomic signature. a PLS-DA analyses shows that metabolome is able to discriminate
between those patients who survive and those patients who do not survive, with those metabolites contributing to separation shown in the VIP
score graph (c). b Heatmap hierarchical clustering analyses using the 25 metabolites with the lowest p value (T-Student test) indicates that there
is not a perfect clusterization between groups. PLS-DA cross-validation details (4 components): Accuracy: 0.92, R2: 0.97, Q2: -0.189. The negative
value of Q2 means that the model is not all predictive or is overfitted, probably because the low number of not surviving patients
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Fig. 2 ROC curves of those metabolites with a potential identity and higher AUC values (a-f). g ROC curve using the values of all the metabolites
from (a) to (f). h ROC curve using Cortisol and Myristic acid
Table 2 Annotated differential metabolites according to mortality
Name of potential metabolitea t.stat P value* False Discovery Rate corrected p
3-Indolelactic acid 5.6738 5.66E-07 0.0010485
Epinephrine 5.0119 6.15E-06 0.005697
Phenylethanolamine 4.6647 2.07E-05 0.009615
Hydroxyisovaleric acid 3.5859 0.0007228 0.13401
Cortisol 3.2222 0.0021581 0.23536
L-Tryptophan 3.0729 0.0033195 0.30045
Myristic acid 2.4577 0.017226 0.7234
Pyridoxal 2.4207 0.018882 0.74483
Bilirubin 2.3772 0.021017 0.78289
Erythrono-1,4-lactone 2.0616 0.044076 0.88671
Elaidic Acid 2.0106 0.049371 0.88671
*after Student t test
aPotential identity based on isotope distribution, exact mass and retention time similarity with the PCDL from Agilent
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bacteremia [38]. Levels of quinolinic acid in cerebro-
spinal fluid, other of the tryptophan metabolites, are
strongly related to low survival chances in TBI. The fact
that tryptophan metabolism is increased in trauma pa-
tients, even after intravenous aminoacid infusion, is rec-
ognized since long time ago [39].
Concerning myristic acid, this long chain fatty acid has
marked effect in hepatic cells [40], leading to cellular
stress and steatosis. Independent results have revealed
that it also confers cardiovascular risk [41]. Myristic acid
in blood may be the result of increased lypolisis in
adipose tissue, one of the physiological effects of cortisol
and epinephrine. However, why only this fatty acid, and
not other shorter or longer chain fatty acid correlate
with mortality is not known. In cellular terms, myristola-
tion is a key event [42] in immune response, especially
in innate immune response, lymphopoiesis for T cells,
and the formation of the immunological synapse. Of
note, recent evidences link trauma to immune disar-
rangements, through the release of the so-called
damage-associated molecular patterns (DAMPs).
DAMPs are considered danger signals which, paradoxic-
ally, lead to propagation of injuries to remote tissues,
contributing to multiple organ failure and even death
(reviewed in [43]). Whether the changes in myristic acid
are associated to DAMPs buildup, release or signaling is
yet unknown. Other metabolomic works discovered
octanoic and decanoic fatty acids, structurally related to
Fig. 3 Pathway impact of differential metabolites according survival. The 11 differential metabolites annotated (Indolelactic acid, Epinephrine,
Phenylethanolamine, 2-Hydroxyisovaleric acid,Cortisol, L-Tryptophan, Myristic acid, Pyridoxal, Bilirubin, Erythrono-1,4-lactone, Elaidic Acid) were
searched against KEGG pathway library of H Sapiens using an hypergeometric test for over representation analyses. P value is encoded in intensity
of red color of circles (representing pathways) and size of the circles represent the diversity of the pathway, based on the number of metabolites
contained in the pathway
Table 3 Correlation between potential biomarkers of mortality
(n = 48)
APACHE II ISS CORTISOL MYRISTIC ACID
APACHE II –
ISS 0,488* –
CORTISOL 0,245 −0,172 –
MYRISTIC ACID 0,215 −0,067 0,292* –
Values shown are Spearman correlation coefficients with * p < 0,05
APACHE II Acute Physiology and Chronic Health Evaluation, ISS Injury
Severity Score
Table 4 Mortality Risk Model (binary logistic regression)
Variable UNIVARIANT
OR (CI 95%)
MULTIVARIANT
OR (CI 95%)
APACHE II 1,2 (1,0 – 1,5) NS
CORTISOL 1,6 (1,0 – 8,4) NS
MYRISTIC ACID 2,1 (1,1 – 3,9) 2,1 (1,1 – 3,9)
OR Odds Ratio, CI Confidence interval, APACHE II Acute Physiology and Chronic
Health Evaluation
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myristic, as potential biomarkers of severity in TBI pa-
tients [44]. Previous works, employing NMR also uncov-
ered lipids (in their case monounsaturated fatty acids,
triacylglycerol and phospholipids) as predictors for sur-
vival in the context of trauma [45].
Myristic acid belongs to long chain free fatty acids
(FFAs). The relationship of FFAs with a negative out-
come are not new, as their concentrations in plasma are
directly associated to trauma severity scores [46]. Fur-
ther, they are increased after bone fracture [47]. Further,
non-trauma related intensive-care conditions such as
burn or acute pancreatitis injuries also lead to increased
concentrations of FFAs [48–50]. FFAs could trigger
myocardial injury through TLR4 activation [51], and they
have been directly related with cardiovascular mortality
[52]. In the context of trauma, they inhibit the production
of an anti-inflammatory interleukin, IL-10 [53] In
addition, they directly induce necrosis [54] through mem-
brane modifications, which could also include increased
susceptibility to hemolysis, a well-known condition with
negative consequences [55]. Noteworthy, recent data show
that differences in albumin FFA-binding properties could
explain different capacities of albumin infusions to modu-
late cell damage in ICU environment [56]. Of note, previ-
ous works from our work revealed an impact of FFAs as
determinants of lifespan in comparative physiology ap-
proaches [57], highlighting the potential influence of cir-
culating FFAs in insulin signaling and other relevant
physiological processes [58].
Our study shows some limitations. Regarding the selection
of possible biomarkers based on the Student t-test can be
questioned, because its use to study differences between
groups different in size and variance is prone to errors. This
is evident in the box and whisker plots of each of the pro-
posed biomarkers, where some of the highest readings in
the surviving group are very similar to the results of the
non-survivors. Nonetheless, the ROC curves of the selected
biomarkers showed high diagnostic accuracy. PLS-DA
model statistics for non-survival could show some overfit-
ting, due to relative low number of samples. In our cohort,
mortality was low (ca 10%). In addition, almost no mortality
was evident by TBI (which shows a high mortality in the
first 96 h after trauma), and many non-surviving patients
overcoming the first 48 h could show multiorgan failure,
with probably a marked influence in metabolome. Further,
those patients with higher severity could require fluid ther-
apy, thereby also conditioning metabolic profile. Similarly,
differences in metabolomics profiles due to fasting-fed state
before trauma could be also a limitation, as suggested by
data in preclinical models [59]. Additionally, age differences,
mechanisms of trauma, sex, and body mass index could also
impinge changes in metabolome. Of note, this study does
not offer a confirmatory cohort, which may be useful for
enhancing robustness of findings. Further meta-analyses
resulting from exploration with larger datasets/higher
mortality rates/highly stratified injury severities are also
warranted. However, even with these limitations, similarly
sized studies have been reported on the discovery of
metabolome-based biomarkers of mortality [20].
We recognize that finding similar candidates within
other studies which may show some underpowered sam-
pling does not completely validate our findings. How-
ever, these reported studies have been obtained with
different analytical techniques, across different geo-
graphic environments, thereby suggesting a common
pathophysiological foundations. In this respect, the rou-
tine use of LC-MS based metabolomics is still not
achievable in most hospitals, due to cost-benefit con-
straints. Nonetheless, LC-MS based metabolomics are
helpful for proposal of novel potential biomarkers, en-
hancing patient’s stratification. Further, its application
could pave the way for discovery of pathophysiologically
relevant pathways, hereby leading to rationally designed
and personalized therapeutics which should enhance the
prognosis of these patients.
Conclusions
Overall, revealed metabolic pathways disclose a catechol-
amine and cortisol stress response with a potential role
of fatty acid metabolism and degradation of specific
amino acids. Further, the fact that multivariate and ROC
analyses show a better behavior than consolidated clin-
ical markers could be helpful in the search for measures
enhancing prognosis in these patients.
Additional file
Additional file 1: Table S1. Differential metabolites according mortality
(full list). Figure S1. Clinical specificity for metabolomics signature. A. PLS-
DA analyses shows that metabolome is able to discriminate between
those patients who survive and those patients who do not survive.
Although the metabolomic profile of survived patients is homogenous, one
of the non-surviving patients had a specific metabolomic profile (black
arrow). B. Heatmap hierarchical clustering analyses using the 25 metabolites
with the lowest p value (T-Student test) confirms that one patient has a
specific metabolomic profile (black arrow). PLS-DA cross-validation details (4
components): Accuracy: 0.91, R2: 0.96, Q2: -0.141. The negative value of Q2
means that the model is not all predictive or is overfitted, probably because
the low number of not surviving patients. (DOCX 239 kb)
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